JP2005508875A5 - - Google Patents

Download PDF

Info

Publication number
JP2005508875A5
JP2005508875A5 JP2003508978A JP2003508978A JP2005508875A5 JP 2005508875 A5 JP2005508875 A5 JP 2005508875A5 JP 2003508978 A JP2003508978 A JP 2003508978A JP 2003508978 A JP2003508978 A JP 2003508978A JP 2005508875 A5 JP2005508875 A5 JP 2005508875A5
Authority
JP
Japan
Prior art keywords
protein
amino acid
acid sequence
conjugate
conjugate according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003508978A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005508875A (ja
Filing date
Publication date
Priority claimed from GBGB0116047.2A external-priority patent/GB0116047D0/en
Application filed filed Critical
Publication of JP2005508875A publication Critical patent/JP2005508875A/ja
Publication of JP2005508875A5 publication Critical patent/JP2005508875A5/ja
Pending legal-status Critical Current

Links

JP2003508978A 2001-06-29 2002-07-01 転座因子として使用するためのペプチド Pending JP2005508875A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0116047.2A GB0116047D0 (en) 2001-06-29 2001-06-29 Peptide motif for therapy
PCT/GB2002/003027 WO2003002598A2 (en) 2001-06-29 2002-07-01 Peptides for use as translocation factors

Publications (2)

Publication Number Publication Date
JP2005508875A JP2005508875A (ja) 2005-04-07
JP2005508875A5 true JP2005508875A5 (enExample) 2006-01-05

Family

ID=9917697

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003508978A Pending JP2005508875A (ja) 2001-06-29 2002-07-01 転座因子として使用するためのペプチド

Country Status (7)

Country Link
US (1) US20040234527A1 (enExample)
EP (1) EP1399570A2 (enExample)
JP (1) JP2005508875A (enExample)
CA (1) CA2451236A1 (enExample)
GB (1) GB0116047D0 (enExample)
IL (1) IL158742A0 (enExample)
WO (1) WO2003002598A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
WO2003007889A2 (en) 2001-07-17 2003-01-30 Research Development Foundation Therapeutic agents comprising pro-apoptotic proteins
US7411048B2 (en) * 2002-11-19 2008-08-12 Drg International, Inc. Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids
US7749713B2 (en) * 2002-11-19 2010-07-06 Hasan Kulaksiz Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
US8017737B2 (en) 2002-11-19 2011-09-13 Hasan Kulaksiz Diagnostic methods for diseases by screening for hepcidin in human or animal tissues, blood or body fluids; monoclonal antibodies specific to human hepcidin and associated uses therefor
US20050032173A1 (en) * 2003-08-05 2005-02-10 Mauricio Rojas Fusion proteins with a membrane translocating sequence and methods of using same to inhibit an immune response
WO2007047907A2 (en) 2005-10-14 2007-04-26 The Regents Of The University Of Michigan Dek protein compositions and methods of using the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993025197A1 (en) * 1992-06-12 1993-12-23 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
EP0998577B1 (en) * 1997-07-24 2004-10-27 Perseptive Biosystems, Inc. Conjugates of transporter peptides and nucleic acid analogs, and their use
IL151909A0 (en) * 2000-04-12 2003-04-10 Implyx Ltd Peptide conjugates for drug delivery
WO2002062823A2 (en) * 2001-02-02 2002-08-15 Yale University Peptides for facilitating composite receptor expression and translocation of macromolecules

Similar Documents

Publication Publication Date Title
US20220306704A1 (en) Neurotoxins for use in inhibiting cgrp
AU2008296733B2 (en) VEGFR-1/NRP-1 targeting peptides
CN107674114A (zh) 用于降低甲状旁腺激素水平的治疗剂
JP2005506340A5 (enExample)
CN109985228A (zh) 拟钙剂及其使用方法
US11419954B2 (en) Targeted protein contrast agents, methods of making, and uses thereof
RU2002130203A (ru) Пептидные конъюгаты для доставки лекарственного средства
CN103080125A (zh) 用于治疗性结合物的短且含d氨基酸的多肽及其使用
CN107312069A (zh) 兴奋性神经毒性相关损伤的治疗肽
KR20190067219A (ko) 통증 예방, 경감 또는 치료에서의 신경 흥분성 상해 관련 폴리펩타이드의 용도
CN1879888B (zh) 透皮给药增强剂及其使用方法
EP1702929A3 (en) Therapeutic use of the smr1 protein and active derivatives thereof
CN100509055C (zh) 使用凝血酶衍生的缩氨酸治疗慢性真皮溃疡
CN106084006B (zh) 一种透皮肽及其应用
JP2005508875A5 (enExample)
CN1433429A (zh) 寡肽
DE602004001509T2 (de) Verwendung von hsp20 zur förderung der wundheilung und / oder zur reduzierung von narbenbildung
JP2022535086A (ja) 修飾ペプチドおよび関連する使用方法
JPWO2006001542A1 (ja) 毒素中和性ペプチドのスクリーニング方法とstx2阻害性ペプチド並びにベロ毒素中和剤
TW201809013A (zh) 用於藥物遞送之抗體融合蛋白
JP6953537B2 (ja) 生物活性が改善され好中球エラスターゼ分解に対する感受性が低下した、フィブロネクチンに由来するペプチド
US10588939B2 (en) Method of treating a bladder cancer using a chimeric EGF-targeted bacterial toxin
CN107312071A (zh) 兴奋性神经毒性相关损伤的治疗方法
EP4648789A1 (en) Use of the recombinant fibrinogen-like domain of angiopoietin-like 4 for treating adverse post-ischemic cardiac remodeling in a patient who experienced a myocardial infarction
WO2024175887A1 (en) Compositions and methods of using c/ebp alpha sarna